Treatment of early-stage esophageal adenocarcinoma

Ariel Polish, Mary F. Mulcahy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Although T2,N0,M0 esophageal adenocarcinoma is grouped with other locoregional disease by NCCN, no consensus exists about how it should be treated. One of the inherent complexities of treating T2,N0,M0 esophageal adenocarcinoma is the inaccuracy of the clinical staging. In addition, conflicting evidence exists about whether neoadjuvant therapy adds any benefit to esophagectomy. A 52-year-old patient recently seen at the Robert H. Lurie Comprehensive Cancer Center illustrates the complexity of these issues.

Original languageEnglish (US)
Pages (from-to)640-644
Number of pages5
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number6
StatePublished - Jun 1 2013

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Treatment of early-stage esophageal adenocarcinoma'. Together they form a unique fingerprint.

Cite this